[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftlM_a1GacpR5WhPKcIOh3fIsQn3c1JnW0dLyownfJC8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":80,"rows":87},"Shionogi",[4],76,false,9,22,35061,13,2,[14,17,20,22,25,28,30,32],{"name":15,"count":16},"Obesity",7,{"name":18,"count":19},"Atrophy",6,{"name":21,"count":19},"Vaginal Diseases",{"name":23,"count":24},"Opioid-induced Constipation",4,{"name":26,"count":27},"Hospital Acquired Pneumonia (HAP)",3,{"name":29,"count":27},"Complicated Urinary Tract Infection (cUTI)",{"name":31,"count":27},"Healthy Participants",{"name":33,"count":27},"Healthy Volunteers",[35,40,45,50,55,60,65,70,75],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT07217886","A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls","2026-06-05","S-892216-PO",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05588323","Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids","2026-06-15","Naldemedine",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05953480","A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke","2026-06-30","Redasemtide",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07214571","A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease","2026-12-30","S-337395",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06776432","Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea","2026-12-31","Sivopixant",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT07093580","Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants","2027-05-26","S-892216-LAI",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT07123155","Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)","2027-08-08","S-606001",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05101070","S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors","2028-05-31","S-531011",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06717438","Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])","2030-01-31","BPN14770",[81,82,83,84,85,86],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[88,170,224,255,276,297,320,338,356,379,397,415,435,455,508,552,599,629,666,688,724,758,788,817,842,860,885,903,929,954,981,999,1017,1064,1100,1136,1173,1207,1225,1243,1272,1290,1308,1326,1344,1362,1388,1412,1438,1464,1482,1508,1526,1544,1574,1592,1610,1628,1646,1664,1682,1710,1728,1746,1764,1814,1832,1857,1875,1899,1928,1946,1964,1982,2000,2024,2049,2073,2091,2109,2135,2153,2171],{"intervention":44,"totalTrials":16,"cells":89},{"EARLY_PHASE1":90,"PHASE1":93,"PHASE2":95,"PHASE3":137,"PHASE4":166,"NA":168},{"trials":91,"activeCount":92},[],0,{"trials":94,"activeCount":92},[],{"trials":96,"activeCount":136,"soonestReadout":43},[97,105,115,125],{"nctId":41,"briefTitle":42,"status":98,"phases":99,"primaryCompletion":43,"completion":43,"start":100,"enrollment":101,"conditions":102,"interventions":104},"RECRUITING",[82,83],"2023-01-04",24,[103],"Opioid-Induced Constipation (OIC)",[44],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":12,"conditions":112,"interventions":114},"NCT04355169","A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection","TERMINATED",[83],"2021-01-04","2020-11-06",[113],"Postoperative Gastrointestinal Dysfunction",[44],{"nctId":116,"briefTitle":117,"status":118,"phases":119,"primaryCompletion":120,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":124},"NCT01443403","A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy","COMPLETED",[83],"2012-08-22","2011-08-17",244,[23],[44],{"nctId":126,"briefTitle":127,"status":118,"phases":128,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":135},"NCT01122030","Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain",[83],"2011-02-23","2011-03-22","2010-05-19",72,[134],"Opioid Induced Bowel Dysfunction",[44],1,{"trials":138,"activeCount":92},[139,148,157],{"nctId":140,"briefTitle":141,"status":118,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":147},"NCT01965158","Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation",[84],"2015-01-22","2013-08-29",547,[23],[44],{"nctId":149,"briefTitle":150,"status":118,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":156},"NCT01993940","Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation",[84],"2015-06-09","2013-11-04",553,[23],[44],{"nctId":158,"briefTitle":159,"status":118,"phases":160,"primaryCompletion":161,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":165},"NCT01965652","Long Term Safety of Naldemedine",[84],"2016-01-12","2013-09-24",1246,[23],[44],{"trials":167,"activeCount":92},[],{"trials":169,"activeCount":92},[],{"intervention":79,"totalTrials":24,"cells":171},{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":207,"PHASE3":218,"PHASE4":220,"NA":222},{"trials":173,"activeCount":92},[],{"trials":175,"activeCount":92},[176,187,197],{"nctId":177,"briefTitle":178,"status":118,"phases":179,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":185},"NCT07011992","A Study to Assess the Effects of BPN14770 on Rosuvastatin",[82],"2025-07-31","2025-08-07","2025-07-18",12,[31],[186,79],"Rosuvastatin",{"nctId":188,"briefTitle":189,"status":118,"phases":190,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":196},"NCT07018492","Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls",[82],"2025-11-26","2025-08-30",32,[195],"Hepatic Impairment",[79],{"nctId":198,"briefTitle":199,"status":118,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":206},"NCT07012005","Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls",[82],"2025-12-15","2025-08-25",14,[205],"Renal Impairment",[79],{"trials":208,"activeCount":136,"soonestReadout":78},[209],{"nctId":76,"briefTitle":77,"status":210,"phases":211,"primaryCompletion":78,"completion":78,"start":212,"enrollment":213,"conditions":214,"interventions":217},"ACTIVE_NOT_RECRUITING",[83],"2025-05-13",30,[215,216],"Jordan's Syndrome","PPP2R5D Neurodevelopmental Disorder",[79],{"trials":219,"activeCount":92},[],{"trials":221,"activeCount":92},[],{"trials":223,"activeCount":92},[],{"intervention":54,"totalTrials":12,"cells":225},{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":240,"PHASE3":249,"PHASE4":251,"NA":253},{"trials":227,"activeCount":92},[],{"trials":229,"activeCount":92},[230],{"nctId":231,"briefTitle":232,"status":118,"phases":233,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":239},"NCT06270511","A Study to Investigate Different Formulations of S-337395 in Healthy Adult Participants",[82],"2024-05-30","2024-06-19","2024-03-13",50,[33],[54],{"trials":241,"activeCount":136,"soonestReadout":53},[242],{"nctId":51,"briefTitle":52,"status":98,"phases":243,"primaryCompletion":53,"completion":53,"start":244,"enrollment":245,"conditions":246,"interventions":248},[83],"2025-12-11",192,[247],"Respiratory Syncytial Virus Infections",[54],{"trials":250,"activeCount":92},[],{"trials":252,"activeCount":92},[],{"trials":254,"activeCount":92},[],{"intervention":69,"totalTrials":136,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":270,"PHASE4":272,"NA":274},{"trials":258,"activeCount":92},[],{"trials":260,"activeCount":92},[],{"trials":262,"activeCount":136,"soonestReadout":68},[263],{"nctId":66,"briefTitle":67,"status":98,"phases":264,"primaryCompletion":68,"completion":68,"start":265,"enrollment":266,"conditions":267,"interventions":269},[83],"2025-10-30",45,[268],"Pompe Disease",[69],{"trials":271,"activeCount":92},[],{"trials":273,"activeCount":92},[],{"trials":275,"activeCount":92},[],{"intervention":49,"totalTrials":136,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":291,"PHASE4":293,"NA":295},{"trials":279,"activeCount":92},[],{"trials":281,"activeCount":92},[],{"trials":283,"activeCount":136,"soonestReadout":48},[284],{"nctId":46,"briefTitle":47,"status":210,"phases":285,"primaryCompletion":48,"completion":48,"start":286,"enrollment":287,"conditions":288,"interventions":290},[83],"2023-07-14",680,[289],"Acute Ischemic Stroke",[49],{"trials":292,"activeCount":92},[],{"trials":294,"activeCount":92},[],{"trials":296,"activeCount":92},[],{"intervention":74,"totalTrials":136,"cells":298},{"EARLY_PHASE1":299,"PHASE1":301,"PHASE2":303,"PHASE3":314,"PHASE4":316,"NA":318},{"trials":300,"activeCount":92},[],{"trials":302,"activeCount":92},[],{"trials":304,"activeCount":136,"soonestReadout":73},[305],{"nctId":71,"briefTitle":72,"status":98,"phases":306,"primaryCompletion":73,"completion":73,"start":307,"enrollment":308,"conditions":309,"interventions":311},[82,83],"2022-05-30",282,[310],"Solid Tumors",[74,312,313],"Pembrolizumab","Bevacizumab",{"trials":315,"activeCount":92},[],{"trials":317,"activeCount":92},[],{"trials":319,"activeCount":92},[],{"intervention":312,"totalTrials":136,"cells":321},{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":332,"PHASE4":334,"NA":336},{"trials":323,"activeCount":92},[],{"trials":325,"activeCount":92},[],{"trials":327,"activeCount":136,"soonestReadout":73},[328],{"nctId":71,"briefTitle":72,"status":98,"phases":329,"primaryCompletion":73,"completion":73,"start":307,"enrollment":308,"conditions":330,"interventions":331},[82,83],[310],[74,312,313],{"trials":333,"activeCount":92},[],{"trials":335,"activeCount":92},[],{"trials":337,"activeCount":92},[],{"intervention":313,"totalTrials":136,"cells":339},{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":350,"PHASE4":352,"NA":354},{"trials":341,"activeCount":92},[],{"trials":343,"activeCount":92},[],{"trials":345,"activeCount":136,"soonestReadout":73},[346],{"nctId":71,"briefTitle":72,"status":98,"phases":347,"primaryCompletion":73,"completion":73,"start":307,"enrollment":308,"conditions":348,"interventions":349},[82,83],[310],[74,312,313],{"trials":351,"activeCount":92},[],{"trials":353,"activeCount":92},[],{"trials":355,"activeCount":92},[],{"intervention":59,"totalTrials":136,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":373,"PHASE4":375,"NA":377},{"trials":359,"activeCount":92},[],{"trials":361,"activeCount":92},[],{"trials":363,"activeCount":136,"soonestReadout":58},[364],{"nctId":56,"briefTitle":57,"status":210,"phases":365,"primaryCompletion":58,"completion":58,"start":366,"enrollment":367,"conditions":368,"interventions":370},[83],"2025-04-02",60,[369],"Sleep Apnea",[59,371,372],"Acetazolamide","SASS-001",{"trials":374,"activeCount":92},[],{"trials":376,"activeCount":92},[],{"trials":378,"activeCount":92},[],{"intervention":371,"totalTrials":136,"cells":380},{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":391,"PHASE4":393,"NA":395},{"trials":382,"activeCount":92},[],{"trials":384,"activeCount":92},[],{"trials":386,"activeCount":136,"soonestReadout":58},[387],{"nctId":56,"briefTitle":57,"status":210,"phases":388,"primaryCompletion":58,"completion":58,"start":366,"enrollment":367,"conditions":389,"interventions":390},[83],[369],[59,371,372],{"trials":392,"activeCount":92},[],{"trials":394,"activeCount":92},[],{"trials":396,"activeCount":92},[],{"intervention":372,"totalTrials":136,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":409,"PHASE4":411,"NA":413},{"trials":400,"activeCount":92},[],{"trials":402,"activeCount":92},[],{"trials":404,"activeCount":136,"soonestReadout":58},[405],{"nctId":56,"briefTitle":57,"status":210,"phases":406,"primaryCompletion":58,"completion":58,"start":366,"enrollment":367,"conditions":407,"interventions":408},[83],[369],[59,371,372],{"trials":410,"activeCount":92},[],{"trials":412,"activeCount":92},[],{"trials":414,"activeCount":92},[],{"intervention":39,"totalTrials":136,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":427,"PHASE3":429,"PHASE4":431,"NA":433},{"trials":418,"activeCount":92},[],{"trials":420,"activeCount":136,"soonestReadout":38},[421],{"nctId":36,"briefTitle":37,"status":98,"phases":422,"primaryCompletion":38,"completion":38,"start":423,"enrollment":424,"conditions":425,"interventions":426},[82],"2025-10-16",40,[205],[39],{"trials":428,"activeCount":92},[],{"trials":430,"activeCount":92},[],{"trials":432,"activeCount":92},[],{"trials":434,"activeCount":92},[],{"intervention":64,"totalTrials":136,"cells":436},{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":447,"PHASE3":449,"PHASE4":451,"NA":453},{"trials":438,"activeCount":92},[],{"trials":440,"activeCount":136,"soonestReadout":63},[441],{"nctId":61,"briefTitle":62,"status":98,"phases":442,"primaryCompletion":63,"completion":63,"start":443,"enrollment":444,"conditions":445,"interventions":446},[82],"2025-07-29",98,[31],[64],{"trials":448,"activeCount":92},[],{"trials":450,"activeCount":92},[],{"trials":452,"activeCount":92},[],{"trials":454,"activeCount":92},[],{"intervention":456,"totalTrials":24,"cells":457},"S-217622",{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":479,"PHASE3":481,"PHASE4":504,"NA":506},{"trials":459,"activeCount":92},[],{"trials":461,"activeCount":92},[462,471],{"nctId":463,"briefTitle":464,"status":118,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":470},"NCT05409911","A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants",[82],"2023-04-25","2022-09-13",25,[195],[456],{"nctId":472,"briefTitle":473,"status":118,"phases":474,"primaryCompletion":475,"completion":475,"start":476,"enrollment":193,"conditions":477,"interventions":478},"NCT05363215","A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants",[82],"2023-04-12","2022-08-10",[205],[456],{"trials":480,"activeCount":92},[],{"trials":482,"activeCount":92},[483,494],{"nctId":484,"briefTitle":485,"status":118,"phases":486,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":493},"NCT05897541","Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection",[84],"2024-08-30","2024-09-18","2023-06-09",2387,[492],"SARS-CoV-2 Infection",[456],{"nctId":495,"briefTitle":496,"status":118,"phases":497,"primaryCompletion":498,"completion":499,"start":500,"enrollment":501,"conditions":502,"interventions":503},"NCT05305547","A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19",[84],"2024-01-07","2024-05-24","2022-08-03",2093,[492],[456],{"trials":505,"activeCount":92},[],{"trials":507,"activeCount":92},[],{"intervention":509,"totalTrials":27,"cells":510},"Ospemifene 60 mg",{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":548,"NA":550},{"trials":512,"activeCount":92},[],{"trials":514,"activeCount":92},[],{"trials":516,"activeCount":92},[],{"trials":518,"activeCount":92},[519,528,537],{"nctId":520,"briefTitle":521,"status":118,"phases":522,"primaryCompletion":523,"completion":523,"start":524,"enrollment":525,"conditions":526,"interventions":527},"NCT00566982","A Clinical Study to Evaluate the Safety of Ospemifene",[84],"2009-07","2007-10",426,[18,21],[509],{"nctId":529,"briefTitle":530,"status":118,"phases":531,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":535,"interventions":536},"NCT00729469","Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity",[84],"2009-08","2008-07",919,[18,21],[509],{"nctId":538,"briefTitle":539,"status":118,"phases":540,"completion":541,"start":542,"enrollment":543,"conditions":544,"interventions":545},"NCT00276094","A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women",[84],"2007-12","2006-01",826,[18,21],[546,509,547],"Ospemifene 30 mg","Nonhormonal vaginal lubricant",{"trials":549,"activeCount":92},[],{"trials":551,"activeCount":92},[],{"intervention":553,"totalTrials":27,"cells":554},"Lusutrombopag",{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":581,"PHASE4":595,"NA":597},{"trials":556,"activeCount":92},[],{"trials":558,"activeCount":92},[],{"trials":560,"activeCount":92},[561,571],{"nctId":562,"briefTitle":563,"status":108,"phases":564,"primaryCompletion":565,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":570},"NCT01129024","An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)",[83],"2011-06-30","2010-04-29",19,[569],"Immune Thrombocytopenia",[553],{"nctId":572,"briefTitle":573,"status":108,"phases":574,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":580},"NCT01054443","A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)",[83],"2010-11-24","2010-03-18",20,[579],"Immune Thrombocytopenia (ITP)",[553],{"trials":582,"activeCount":92},[583],{"nctId":584,"briefTitle":585,"status":118,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":594},"NCT02389621","Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures",[84],"2017-04-05","2017-04-19","2015-06-15",215,[592,593],"Chronic Liver Disease","Thrombocytopenia",[553],{"trials":596,"activeCount":92},[],{"trials":598,"activeCount":92},[],{"intervention":546,"totalTrials":12,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":619,"PHASE4":625,"NA":627},{"trials":602,"activeCount":92},[],{"trials":604,"activeCount":92},[],{"trials":606,"activeCount":92},[607],{"nctId":608,"briefTitle":609,"status":118,"phases":610,"primaryCompletion":611,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":616},"NCT00630539","A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women",[83],"2008-01","2008-02","2007-08",126,[18,21],[617,618,546],"Ospemifene 5 mg","Ospemifene 15 mg",{"trials":620,"activeCount":92},[621],{"nctId":538,"briefTitle":539,"status":118,"phases":622,"completion":541,"start":542,"enrollment":543,"conditions":623,"interventions":624},[84],[18,21],[546,509,547],{"trials":626,"activeCount":92},[],{"trials":628,"activeCount":92},[],{"intervention":630,"totalTrials":12,"cells":631},"Baloxavir Marboxil",{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":638,"PHASE4":662,"NA":664},{"trials":633,"activeCount":92},[],{"trials":635,"activeCount":92},[],{"trials":637,"activeCount":92},[],{"trials":639,"activeCount":92},[640,652],{"nctId":641,"briefTitle":642,"status":118,"phases":643,"primaryCompletion":644,"completion":645,"start":646,"enrollment":647,"conditions":648,"interventions":650},"NCT02949011","Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications",[84],"2018-04-12","2018-04-20","2017-01-11",2184,[649],"Influenza",[630,651],"Oseltamivir",{"nctId":653,"briefTitle":654,"status":118,"phases":655,"primaryCompletion":656,"completion":657,"start":658,"enrollment":659,"conditions":660,"interventions":661},"NCT02954354","A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza",[84],"2017-04-04","2017-04-24","2016-12-08",1436,[649],[630,651],{"trials":663,"activeCount":92},[],{"trials":665,"activeCount":92},[],{"intervention":651,"totalTrials":12,"cells":667},{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":674,"PHASE4":684,"NA":686},{"trials":669,"activeCount":92},[],{"trials":671,"activeCount":92},[],{"trials":673,"activeCount":92},[],{"trials":675,"activeCount":92},[676,680],{"nctId":641,"briefTitle":642,"status":118,"phases":677,"primaryCompletion":644,"completion":645,"start":646,"enrollment":647,"conditions":678,"interventions":679},[84],[649],[630,651],{"nctId":653,"briefTitle":654,"status":118,"phases":681,"primaryCompletion":656,"completion":657,"start":658,"enrollment":659,"conditions":682,"interventions":683},[84],[649],[630,651],{"trials":685,"activeCount":92},[],{"trials":687,"activeCount":92},[],{"intervention":689,"totalTrials":12,"cells":690},"Ospemifene",{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":695,"PHASE3":697,"PHASE4":720,"NA":722},{"trials":692,"activeCount":92},[],{"trials":694,"activeCount":92},[],{"trials":696,"activeCount":92},[],{"trials":698,"activeCount":92},[699,709],{"nctId":700,"briefTitle":701,"status":118,"phases":702,"primaryCompletion":703,"completion":704,"start":705,"enrollment":706,"conditions":707,"interventions":708},"NCT01585558","Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus",[84],"2008-08-19","2008-09-18","2006-05-16",180,[18,21],[689,689],{"nctId":710,"briefTitle":711,"status":118,"phases":712,"primaryCompletion":713,"completion":714,"start":715,"enrollment":716,"conditions":717,"interventions":719},"NCT02638337","Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause",[84],"2017-06-23","2017-07-05","2016-01-26",631,[718],"Vaginal Dryness",[689],{"trials":721,"activeCount":92},[],{"trials":723,"activeCount":92},[],{"intervention":725,"totalTrials":12,"cells":726},"Duloxetine Hydrochloride",{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":733,"PHASE4":754,"NA":756},{"trials":728,"activeCount":92},[],{"trials":730,"activeCount":92},[],{"trials":732,"activeCount":92},[],{"trials":734,"activeCount":92},[735,745],{"nctId":736,"briefTitle":737,"status":108,"phases":738,"primaryCompletion":739,"completion":739,"start":740,"enrollment":741,"conditions":742,"interventions":744},"NCT03395353","A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder",[84],"2020-07-04","2018-01-29",151,[743],"Depressive Disorder",[725],{"nctId":746,"briefTitle":747,"status":118,"phases":748,"primaryCompletion":749,"completion":749,"start":750,"enrollment":751,"conditions":752,"interventions":753},"NCT03315793","A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder",[84],"2019-11-08","2017-12-04",149,[743],[725],{"trials":755,"activeCount":92},[],{"trials":757,"activeCount":92},[],{"intervention":759,"totalTrials":136,"cells":760},"Best Available Therapy",{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":784,"NA":786},{"trials":762,"activeCount":92},[],{"trials":764,"activeCount":92},[],{"trials":766,"activeCount":92},[],{"trials":768,"activeCount":92},[769],{"nctId":770,"briefTitle":771,"status":118,"phases":772,"primaryCompletion":773,"completion":774,"start":775,"enrollment":776,"conditions":777,"interventions":782},"NCT02714595","Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens",[84],"2019-04-01","2019-04-22","2016-09-07",152,[778,779,26,29,780,781],"Healthcare-associated Pneumonia (HCAP)","Bloodstream Infections (BSI)","Sepsis","Ventilator Associated Pneumonia (VAP)",[783,759],"Cefiderocol",{"trials":785,"activeCount":92},[],{"trials":787,"activeCount":92},[],{"intervention":789,"totalTrials":136,"cells":790},"Oral Glycopyrrolate Liquid",{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":795,"PHASE3":797,"PHASE4":813,"NA":815},{"trials":792,"activeCount":92},[],{"trials":794,"activeCount":92},[],{"trials":796,"activeCount":92},[],{"trials":798,"activeCount":92},[799],{"nctId":800,"briefTitle":801,"status":118,"phases":802,"primaryCompletion":803,"completion":804,"start":805,"enrollment":806,"conditions":807,"interventions":812},"NCT00491894","Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions",[84],"2008-05","2008-06","2007-03",137,[808,809,810,811],"Cerebral Palsy","Neurological Conditions","Mental Retardation","Sialorrhea",[789],{"trials":814,"activeCount":92},[],{"trials":816,"activeCount":92},[],{"intervention":818,"totalTrials":136,"cells":819},"CLONICEL",{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":838,"NA":840},{"trials":821,"activeCount":92},[],{"trials":823,"activeCount":92},[],{"trials":825,"activeCount":92},[],{"trials":827,"activeCount":92},[828],{"nctId":829,"briefTitle":830,"status":118,"phases":831,"primaryCompletion":832,"completion":833,"start":611,"enrollment":834,"conditions":835,"interventions":837},"NCT00723190","Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)",[84],"2010-03","2010-06",303,[836],"Attention Deficit Hyperactivity Disorder",[818],{"trials":839,"activeCount":92},[],{"trials":841,"activeCount":92},[],{"intervention":547,"totalTrials":136,"cells":843},{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":848,"PHASE3":850,"PHASE4":856,"NA":858},{"trials":845,"activeCount":92},[],{"trials":847,"activeCount":92},[],{"trials":849,"activeCount":92},[],{"trials":851,"activeCount":92},[852],{"nctId":538,"briefTitle":539,"status":118,"phases":853,"completion":541,"start":542,"enrollment":543,"conditions":854,"interventions":855},[84],[18,21],[546,509,547],{"trials":857,"activeCount":92},[],{"trials":859,"activeCount":92},[],{"intervention":861,"totalTrials":136,"cells":862},"Meropenem",{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":869,"PHASE4":881,"NA":883},{"trials":864,"activeCount":92},[],{"trials":866,"activeCount":92},[],{"trials":868,"activeCount":92},[],{"trials":870,"activeCount":92},[871],{"nctId":872,"briefTitle":873,"status":118,"phases":874,"primaryCompletion":875,"completion":773,"start":876,"enrollment":877,"conditions":878,"interventions":879},"NCT03032380","Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens",[84],"2019-02-26","2017-10-24",300,[778,26,781],[783,861,880],"Linezolid",{"trials":882,"activeCount":92},[],{"trials":884,"activeCount":92},[],{"intervention":880,"totalTrials":136,"cells":886},{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":893,"PHASE4":899,"NA":901},{"trials":888,"activeCount":92},[],{"trials":890,"activeCount":92},[],{"trials":892,"activeCount":92},[],{"trials":894,"activeCount":92},[895],{"nctId":872,"briefTitle":873,"status":118,"phases":896,"primaryCompletion":875,"completion":773,"start":876,"enrollment":877,"conditions":897,"interventions":898},[84],[778,26,781],[783,861,880],{"trials":900,"activeCount":92},[],{"trials":902,"activeCount":92},[],{"intervention":904,"totalTrials":136,"cells":905},"S-268019-b",{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":925,"NA":927},{"trials":907,"activeCount":92},[],{"trials":909,"activeCount":92},[],{"trials":911,"activeCount":92},[],{"trials":913,"activeCount":92},[914],{"nctId":915,"briefTitle":916,"status":118,"phases":917,"primaryCompletion":918,"completion":919,"start":920,"enrollment":921,"conditions":922,"interventions":924},"NCT05212948","A Study of S-268019 for the Prevention of COVID-19",[84],"2022-12-19","2023-07-19","2021-12-25",9902,[923],"SARS-CoV-2",[904],{"trials":926,"activeCount":92},[],{"trials":928,"activeCount":92},[],{"intervention":930,"totalTrials":136,"cells":931},"Ospemifene 60Mg Oral",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":950,"NA":952},{"trials":933,"activeCount":92},[],{"trials":935,"activeCount":92},[],{"trials":937,"activeCount":92},[],{"trials":939,"activeCount":92},[940],{"nctId":941,"briefTitle":942,"status":118,"phases":943,"primaryCompletion":944,"completion":945,"start":946,"enrollment":947,"conditions":948,"interventions":949},"NCT01586364","Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus",[84],"2008-11-21","2008-12-22","2006-05-08",301,[18,21],[930],{"trials":951,"activeCount":92},[],{"trials":953,"activeCount":92},[],{"intervention":955,"totalTrials":136,"cells":956},"Pravafen",{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":963,"PHASE4":977,"NA":979},{"trials":958,"activeCount":92},[],{"trials":960,"activeCount":92},[],{"trials":962,"activeCount":92},[],{"trials":964,"activeCount":92},[965],{"nctId":966,"briefTitle":967,"status":118,"phases":968,"primaryCompletion":969,"completion":523,"start":970,"enrollment":971,"conditions":972,"interventions":974},"NCT00459745","A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia",[84],"2008-04","2007-04",481,[973],"Combined Hyperlipidemia",[955,975,976],"Pravastatin","Fenofibrate",{"trials":978,"activeCount":92},[],{"trials":980,"activeCount":92},[],{"intervention":975,"totalTrials":136,"cells":982},{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":989,"PHASE4":995,"NA":997},{"trials":984,"activeCount":92},[],{"trials":986,"activeCount":92},[],{"trials":988,"activeCount":92},[],{"trials":990,"activeCount":92},[991],{"nctId":966,"briefTitle":967,"status":118,"phases":992,"primaryCompletion":969,"completion":523,"start":970,"enrollment":971,"conditions":993,"interventions":994},[84],[973],[955,975,976],{"trials":996,"activeCount":92},[],{"trials":998,"activeCount":92},[],{"intervention":976,"totalTrials":136,"cells":1000},{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1005,"PHASE3":1007,"PHASE4":1013,"NA":1015},{"trials":1002,"activeCount":92},[],{"trials":1004,"activeCount":92},[],{"trials":1006,"activeCount":92},[],{"trials":1008,"activeCount":92},[1009],{"nctId":966,"briefTitle":967,"status":118,"phases":1010,"primaryCompletion":969,"completion":523,"start":970,"enrollment":971,"conditions":1011,"interventions":1012},[84],[973],[955,975,976],{"trials":1014,"activeCount":92},[],{"trials":1016,"activeCount":92},[],{"intervention":1018,"totalTrials":27,"cells":1019},"Standard of Care",{"EARLY_PHASE1":1020,"PHASE1":1022,"PHASE2":1024,"PHASE3":1058,"PHASE4":1060,"NA":1062},{"trials":1021,"activeCount":92},[],{"trials":1023,"activeCount":92},[],{"trials":1025,"activeCount":92},[1026,1035,1047],{"nctId":1027,"briefTitle":1028,"status":118,"phases":1029,"primaryCompletion":1030,"completion":1030,"start":1031,"enrollment":213,"conditions":1032,"interventions":1034},"NCT06086626","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants",[83],"2025-03-31","2024-03-14",[1033],"Gram-Negative Bacterial Infections",[783,1018],{"nctId":1036,"briefTitle":1037,"status":118,"phases":1038,"primaryCompletion":1039,"completion":1039,"start":1040,"enrollment":1041,"conditions":1042,"interventions":1046},"NCT04335539","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants",[83],"2023-02-06","2020-08-21",53,[1043,779,1044,26,1045,29,780],"Gram-negative Bacterial Infections","Complicated Intra-abdominal Infection (cIAI)","Ventilator-acquired Pneumonia",[783,1018],{"nctId":1048,"briefTitle":1049,"status":118,"phases":1050,"primaryCompletion":1051,"completion":1051,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1057},"NCT04215991","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants",[83],"2024-09-17","2020-02-19",91,[1043,1055,29,1056],"Hospital Acquired Bacterial Pneumonia (HABP)","Ventilator Associated Bacterial Pneumonia (VABP)",[783,1018],{"trials":1059,"activeCount":92},[],{"trials":1061,"activeCount":92},[],{"trials":1063,"activeCount":92},[],{"intervention":1065,"totalTrials":12,"cells":1066},"S-309309",{"EARLY_PHASE1":1067,"PHASE1":1069,"PHASE2":1082,"PHASE3":1094,"PHASE4":1096,"NA":1098},{"trials":1068,"activeCount":92},[],{"trials":1070,"activeCount":92},[1071],{"nctId":1072,"briefTitle":1073,"status":118,"phases":1074,"primaryCompletion":1075,"completion":1076,"start":1077,"enrollment":1078,"conditions":1079,"interventions":1080},"NCT05247970","A Study to Assess S-309309 in Healthy and Obese Participants",[82],"2022-10-20","2022-11-01","2022-01-04",74,[15],[1065,1081],"Midazolam",{"trials":1083,"activeCount":92},[1084],{"nctId":1085,"briefTitle":1086,"status":118,"phases":1087,"primaryCompletion":1088,"completion":1089,"start":1090,"enrollment":1091,"conditions":1092,"interventions":1093},"NCT05925114","Safety and Efficacy Study of S-309309 in Obese Adults",[83],"2024-04-15","2024-05-17","2023-06-21",365,[15],[1065],{"trials":1095,"activeCount":92},[],{"trials":1097,"activeCount":92},[],{"trials":1099,"activeCount":92},[],{"intervention":1101,"totalTrials":12,"cells":1102},"S-2367 Placebo",{"EARLY_PHASE1":1103,"PHASE1":1105,"PHASE2":1107,"PHASE3":1130,"PHASE4":1132,"NA":1134},{"trials":1104,"activeCount":92},[],{"trials":1106,"activeCount":92},[],{"trials":1108,"activeCount":92},[1109,1121],{"nctId":1110,"briefTitle":1111,"status":118,"phases":1112,"primaryCompletion":1113,"completion":1114,"start":1115,"enrollment":1116,"conditions":1117,"interventions":1118},"NCT00747929","Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet",[83],"2008-11","2009-01","2007-06",724,[15],[1101,1119,1120],"S-2367 800 mg","S-2367 1600 mg",{"nctId":1122,"briefTitle":1123,"status":118,"phases":1124,"primaryCompletion":1113,"completion":1114,"start":1115,"enrollment":1125,"conditions":1126,"interventions":1127},"NCT00748605","Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet",[83],842,[15],[1101,1128,1129],"S-2367 1600 mg q.d. 54 Weeks","S-2367 1600 mg q.d. 60 weeks",{"trials":1131,"activeCount":92},[],{"trials":1133,"activeCount":92},[],{"trials":1135,"activeCount":92},[],{"intervention":1137,"totalTrials":12,"cells":1138},"S-3304",{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1152,"PHASE3":1167,"PHASE4":1169,"NA":1171},{"trials":1140,"activeCount":92},[],{"trials":1142,"activeCount":92},[1143],{"nctId":1144,"briefTitle":1145,"status":118,"phases":1146,"primaryCompletion":1147,"completion":1148,"start":1149,"enrollment":193,"conditions":1150,"interventions":1151},"NCT00033215","A Phase 1 Study of S-3304 in Patients With Solid Tumors",[82],"2003-02-13","2003-03-12","2001-11",[310],[1137],{"trials":1153,"activeCount":92},[1154],{"nctId":1155,"briefTitle":1156,"status":118,"phases":1157,"primaryCompletion":1158,"completion":1159,"start":1160,"enrollment":8,"conditions":1161,"interventions":1166},"NCT00078390","Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer",[82,83],"2006-09-28","2006-10-26","2003-02",[1162,1163,1164,1165],"Non Small Cell Lung Cancer","Lung Cancer","Stage IIIA Non Small Cell Lung Cancer","Stage IIIB Non Small Cell Lung Cancer",[1137],{"trials":1168,"activeCount":92},[],{"trials":1170,"activeCount":92},[],{"trials":1172,"activeCount":92},[],{"intervention":1174,"totalTrials":12,"cells":1175},"S-892216",{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1191,"PHASE3":1201,"PHASE4":1203,"NA":1205},{"trials":1177,"activeCount":92},[],{"trials":1179,"activeCount":92},[1180],{"nctId":1181,"briefTitle":1182,"status":118,"phases":1183,"primaryCompletion":1184,"completion":1184,"start":1185,"enrollment":1186,"conditions":1187,"interventions":1189},"NCT06751017","A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants",[82],"2025-02-24","2024-12-17",16,[1188],"COVID-19",[1174,1190],"Carbamazepine",{"trials":1192,"activeCount":92},[1193],{"nctId":1194,"briefTitle":1195,"status":118,"phases":1196,"primaryCompletion":1197,"completion":1197,"start":1198,"enrollment":308,"conditions":1199,"interventions":1200},"NCT06928051","A Study of S-892216 in Participants With COVID-19",[83],"2025-09-22","2025-06-06",[1188],[1174],{"trials":1202,"activeCount":92},[],{"trials":1204,"activeCount":92},[],{"trials":1206,"activeCount":92},[],{"intervention":1119,"totalTrials":136,"cells":1208},{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1219,"PHASE4":1221,"NA":1223},{"trials":1210,"activeCount":92},[],{"trials":1212,"activeCount":92},[],{"trials":1214,"activeCount":92},[1215],{"nctId":1110,"briefTitle":1111,"status":118,"phases":1216,"primaryCompletion":1113,"completion":1114,"start":1115,"enrollment":1116,"conditions":1217,"interventions":1218},[83],[15],[1101,1119,1120],{"trials":1220,"activeCount":92},[],{"trials":1222,"activeCount":92},[],{"trials":1224,"activeCount":92},[],{"intervention":1120,"totalTrials":136,"cells":1226},{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1237,"PHASE4":1239,"NA":1241},{"trials":1228,"activeCount":92},[],{"trials":1230,"activeCount":92},[],{"trials":1232,"activeCount":92},[1233],{"nctId":1110,"briefTitle":1111,"status":118,"phases":1234,"primaryCompletion":1113,"completion":1114,"start":1115,"enrollment":1116,"conditions":1235,"interventions":1236},[83],[15],[1101,1119,1120],{"trials":1238,"activeCount":92},[],{"trials":1240,"activeCount":92},[],{"trials":1242,"activeCount":92},[],{"intervention":1244,"totalTrials":136,"cells":1245},"S-707106 Dose A",{"EARLY_PHASE1":1246,"PHASE1":1248,"PHASE2":1250,"PHASE3":1266,"PHASE4":1268,"NA":1270},{"trials":1247,"activeCount":92},[],{"trials":1249,"activeCount":92},[],{"trials":1251,"activeCount":92},[1252],{"nctId":1253,"briefTitle":1254,"status":118,"phases":1255,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1260,"interventions":1262},"NCT01240759","Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy",[83],"2011-12","2012-01","2010-10",218,[1261],"Type 2 Diabetes Mellitus",[1244,1263,1264,1265],"S-707106 Dose B","S-707106 Dose C","Metformin",{"trials":1267,"activeCount":92},[],{"trials":1269,"activeCount":92},[],{"trials":1271,"activeCount":92},[],{"intervention":1263,"totalTrials":136,"cells":1273},{"EARLY_PHASE1":1274,"PHASE1":1276,"PHASE2":1278,"PHASE3":1284,"PHASE4":1286,"NA":1288},{"trials":1275,"activeCount":92},[],{"trials":1277,"activeCount":92},[],{"trials":1279,"activeCount":92},[1280],{"nctId":1253,"briefTitle":1254,"status":118,"phases":1281,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1282,"interventions":1283},[83],[1261],[1244,1263,1264,1265],{"trials":1285,"activeCount":92},[],{"trials":1287,"activeCount":92},[],{"trials":1289,"activeCount":92},[],{"intervention":1264,"totalTrials":136,"cells":1291},{"EARLY_PHASE1":1292,"PHASE1":1294,"PHASE2":1296,"PHASE3":1302,"PHASE4":1304,"NA":1306},{"trials":1293,"activeCount":92},[],{"trials":1295,"activeCount":92},[],{"trials":1297,"activeCount":92},[1298],{"nctId":1253,"briefTitle":1254,"status":118,"phases":1299,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1300,"interventions":1301},[83],[1261],[1244,1263,1264,1265],{"trials":1303,"activeCount":92},[],{"trials":1305,"activeCount":92},[],{"trials":1307,"activeCount":92},[],{"intervention":1265,"totalTrials":136,"cells":1309},{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1320,"PHASE4":1322,"NA":1324},{"trials":1311,"activeCount":92},[],{"trials":1313,"activeCount":92},[],{"trials":1315,"activeCount":92},[1316],{"nctId":1253,"briefTitle":1254,"status":118,"phases":1317,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1318,"interventions":1319},[83],[1261],[1244,1263,1264,1265],{"trials":1321,"activeCount":92},[],{"trials":1323,"activeCount":92},[],{"trials":1325,"activeCount":92},[],{"intervention":617,"totalTrials":136,"cells":1327},{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1332,"PHASE3":1338,"PHASE4":1340,"NA":1342},{"trials":1329,"activeCount":92},[],{"trials":1331,"activeCount":92},[],{"trials":1333,"activeCount":92},[1334],{"nctId":608,"briefTitle":609,"status":118,"phases":1335,"primaryCompletion":611,"completion":612,"start":613,"enrollment":614,"conditions":1336,"interventions":1337},[83],[18,21],[617,618,546],{"trials":1339,"activeCount":92},[],{"trials":1341,"activeCount":92},[],{"trials":1343,"activeCount":92},[],{"intervention":618,"totalTrials":136,"cells":1345},{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1356,"PHASE4":1358,"NA":1360},{"trials":1347,"activeCount":92},[],{"trials":1349,"activeCount":92},[],{"trials":1351,"activeCount":92},[1352],{"nctId":608,"briefTitle":609,"status":118,"phases":1353,"primaryCompletion":611,"completion":612,"start":613,"enrollment":614,"conditions":1354,"interventions":1355},[83],[18,21],[617,618,546],{"trials":1357,"activeCount":92},[],{"trials":1359,"activeCount":92},[],{"trials":1361,"activeCount":92},[],{"intervention":1363,"totalTrials":136,"cells":1364},"S-600918",{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1369,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1366,"activeCount":92},[],{"trials":1368,"activeCount":92},[],{"trials":1370,"activeCount":92},[1371],{"nctId":1372,"briefTitle":1373,"status":118,"phases":1374,"primaryCompletion":1375,"completion":1376,"start":1377,"enrollment":1378,"conditions":1379,"interventions":1381},"NCT04110054","Evaluation of S-600918 in Adults With Refractory Chronic Cough",[83],"2020-12-08","2020-12-28","2020-02-13",406,[1380],"Chronic Cough",[1363],{"trials":1383,"activeCount":92},[],{"trials":1385,"activeCount":92},[],{"trials":1387,"activeCount":92},[],{"intervention":1389,"totalTrials":136,"cells":1390},"S-2367",{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1406,"PHASE4":1408,"NA":1410},{"trials":1392,"activeCount":92},[],{"trials":1394,"activeCount":92},[],{"trials":1396,"activeCount":92},[1397],{"nctId":1398,"briefTitle":1399,"status":118,"phases":1400,"primaryCompletion":1401,"completion":832,"start":1402,"enrollment":1403,"conditions":1404,"interventions":1405},"NCT00788528","Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects",[83],"2010-02","2008-08",766,[15],[1389],{"trials":1407,"activeCount":92},[],{"trials":1409,"activeCount":92},[],{"trials":1411,"activeCount":92},[],{"intervention":1413,"totalTrials":136,"cells":1414},"Imipenem\u002Fcilastatin",{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1432,"PHASE4":1434,"NA":1436},{"trials":1416,"activeCount":92},[],{"trials":1418,"activeCount":92},[],{"trials":1420,"activeCount":92},[1421],{"nctId":1422,"briefTitle":1423,"status":118,"phases":1424,"primaryCompletion":1425,"completion":1426,"start":1427,"enrollment":1428,"conditions":1429,"interventions":1431},"NCT02321800","A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem\u002FCilastatin in Complicated Urinary Tract Infections",[83],"2016-07-26","2016-08-16","2015-02-05",452,[1430],"Urinary Tract Infections",[783,1413],{"trials":1433,"activeCount":92},[],{"trials":1435,"activeCount":92},[],{"trials":1437,"activeCount":92},[],{"intervention":1439,"totalTrials":136,"cells":1440},"S-777469 400 mg",{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1445,"PHASE3":1458,"PHASE4":1460,"NA":1462},{"trials":1442,"activeCount":92},[],{"trials":1444,"activeCount":92},[],{"trials":1446,"activeCount":92},[1447],{"nctId":1448,"briefTitle":1449,"status":118,"phases":1450,"primaryCompletion":1451,"completion":1452,"start":803,"enrollment":1453,"conditions":1454,"interventions":1456},"NCT00703573","A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis",[83],"2009-05","2009-12",209,[1455],"Atopic Dermatitis",[1439,1457],"S-777469 800 mg",{"trials":1459,"activeCount":92},[],{"trials":1461,"activeCount":92},[],{"trials":1463,"activeCount":92},[],{"intervention":1457,"totalTrials":136,"cells":1465},{"EARLY_PHASE1":1466,"PHASE1":1468,"PHASE2":1470,"PHASE3":1476,"PHASE4":1478,"NA":1480},{"trials":1467,"activeCount":92},[],{"trials":1469,"activeCount":92},[],{"trials":1471,"activeCount":92},[1472],{"nctId":1448,"briefTitle":1449,"status":118,"phases":1473,"primaryCompletion":1451,"completion":1452,"start":803,"enrollment":1453,"conditions":1474,"interventions":1475},[83],[1455],[1439,1457],{"trials":1477,"activeCount":92},[],{"trials":1479,"activeCount":92},[],{"trials":1481,"activeCount":92},[],{"intervention":1483,"totalTrials":136,"cells":1484},"50 mg S-777469",{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1502,"PHASE4":1504,"NA":1506},{"trials":1486,"activeCount":92},[],{"trials":1488,"activeCount":92},[],{"trials":1490,"activeCount":92},[1491],{"nctId":1492,"briefTitle":1493,"status":118,"phases":1494,"primaryCompletion":612,"completion":1495,"start":1496,"enrollment":1497,"conditions":1498,"interventions":1499},"NCT00697710","A Phase Ib\u002FIIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis",[82,83],"2008-09","2007-07",37,[1455],[1483,1500,1501],"200 mg S-777469","800 mg S-777469",{"trials":1503,"activeCount":92},[],{"trials":1505,"activeCount":92},[],{"trials":1507,"activeCount":92},[],{"intervention":1500,"totalTrials":136,"cells":1509},{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1520,"PHASE4":1522,"NA":1524},{"trials":1511,"activeCount":92},[],{"trials":1513,"activeCount":92},[],{"trials":1515,"activeCount":92},[1516],{"nctId":1492,"briefTitle":1493,"status":118,"phases":1517,"primaryCompletion":612,"completion":1495,"start":1496,"enrollment":1497,"conditions":1518,"interventions":1519},[82,83],[1455],[1483,1500,1501],{"trials":1521,"activeCount":92},[],{"trials":1523,"activeCount":92},[],{"trials":1525,"activeCount":92},[],{"intervention":1501,"totalTrials":136,"cells":1527},{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1532,"PHASE3":1538,"PHASE4":1540,"NA":1542},{"trials":1529,"activeCount":92},[],{"trials":1531,"activeCount":92},[],{"trials":1533,"activeCount":92},[1534],{"nctId":1492,"briefTitle":1493,"status":118,"phases":1535,"primaryCompletion":612,"completion":1495,"start":1496,"enrollment":1497,"conditions":1536,"interventions":1537},[82,83],[1455],[1483,1500,1501],{"trials":1539,"activeCount":92},[],{"trials":1541,"activeCount":92},[],{"trials":1543,"activeCount":92},[],{"intervention":1545,"totalTrials":136,"cells":1546},"S-555739 Dose 1",{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1551,"PHASE3":1568,"PHASE4":1570,"NA":1572},{"trials":1548,"activeCount":92},[],{"trials":1550,"activeCount":92},[],{"trials":1552,"activeCount":92},[1553],{"nctId":1554,"briefTitle":1555,"status":118,"phases":1556,"primaryCompletion":1557,"completion":1558,"start":1559,"enrollment":1560,"conditions":1561,"interventions":1563},"NCT01651871","Combination Study Of S-555739\u002FCetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis",[83],"2012-11","2013-05","2012-07",779,[1562],"Seasonal Allergic Rhinitis",[1545,1564,1565,1566,1567],"S-555739 Dose 2","Cetirizine HCl Dose 1","S-555739 placebo","Cetirizine HCl placebo",{"trials":1569,"activeCount":92},[],{"trials":1571,"activeCount":92},[],{"trials":1573,"activeCount":92},[],{"intervention":1564,"totalTrials":136,"cells":1575},{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1586,"PHASE4":1588,"NA":1590},{"trials":1577,"activeCount":92},[],{"trials":1579,"activeCount":92},[],{"trials":1581,"activeCount":92},[1582],{"nctId":1554,"briefTitle":1555,"status":118,"phases":1583,"primaryCompletion":1557,"completion":1558,"start":1559,"enrollment":1560,"conditions":1584,"interventions":1585},[83],[1562],[1545,1564,1565,1566,1567],{"trials":1587,"activeCount":92},[],{"trials":1589,"activeCount":92},[],{"trials":1591,"activeCount":92},[],{"intervention":1565,"totalTrials":136,"cells":1593},{"EARLY_PHASE1":1594,"PHASE1":1596,"PHASE2":1598,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1595,"activeCount":92},[],{"trials":1597,"activeCount":92},[],{"trials":1599,"activeCount":92},[1600],{"nctId":1554,"briefTitle":1555,"status":118,"phases":1601,"primaryCompletion":1557,"completion":1558,"start":1559,"enrollment":1560,"conditions":1602,"interventions":1603},[83],[1562],[1545,1564,1565,1566,1567],{"trials":1605,"activeCount":92},[],{"trials":1607,"activeCount":92},[],{"trials":1609,"activeCount":92},[],{"intervention":1566,"totalTrials":136,"cells":1611},{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1616,"PHASE3":1622,"PHASE4":1624,"NA":1626},{"trials":1613,"activeCount":92},[],{"trials":1615,"activeCount":92},[],{"trials":1617,"activeCount":92},[1618],{"nctId":1554,"briefTitle":1555,"status":118,"phases":1619,"primaryCompletion":1557,"completion":1558,"start":1559,"enrollment":1560,"conditions":1620,"interventions":1621},[83],[1562],[1545,1564,1565,1566,1567],{"trials":1623,"activeCount":92},[],{"trials":1625,"activeCount":92},[],{"trials":1627,"activeCount":92},[],{"intervention":1567,"totalTrials":136,"cells":1629},{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1640,"PHASE4":1642,"NA":1644},{"trials":1631,"activeCount":92},[],{"trials":1633,"activeCount":92},[],{"trials":1635,"activeCount":92},[1636],{"nctId":1554,"briefTitle":1555,"status":118,"phases":1637,"primaryCompletion":1557,"completion":1558,"start":1559,"enrollment":1560,"conditions":1638,"interventions":1639},[83],[1562],[1545,1564,1565,1566,1567],{"trials":1641,"activeCount":92},[],{"trials":1643,"activeCount":92},[],{"trials":1645,"activeCount":92},[],{"intervention":1128,"totalTrials":136,"cells":1647},{"EARLY_PHASE1":1648,"PHASE1":1650,"PHASE2":1652,"PHASE3":1658,"PHASE4":1660,"NA":1662},{"trials":1649,"activeCount":92},[],{"trials":1651,"activeCount":92},[],{"trials":1653,"activeCount":92},[1654],{"nctId":1122,"briefTitle":1123,"status":118,"phases":1655,"primaryCompletion":1113,"completion":1114,"start":1115,"enrollment":1125,"conditions":1656,"interventions":1657},[83],[15],[1101,1128,1129],{"trials":1659,"activeCount":92},[],{"trials":1661,"activeCount":92},[],{"trials":1663,"activeCount":92},[],{"intervention":1129,"totalTrials":136,"cells":1665},{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1670,"PHASE3":1676,"PHASE4":1678,"NA":1680},{"trials":1667,"activeCount":92},[],{"trials":1669,"activeCount":92},[],{"trials":1671,"activeCount":92},[1672],{"nctId":1122,"briefTitle":1123,"status":118,"phases":1673,"primaryCompletion":1113,"completion":1114,"start":1115,"enrollment":1125,"conditions":1674,"interventions":1675},[83],[15],[1101,1128,1129],{"trials":1677,"activeCount":92},[],{"trials":1679,"activeCount":92},[],{"trials":1681,"activeCount":92},[],{"intervention":1683,"totalTrials":136,"cells":1684},"Velneperit 400 mg",{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1704,"PHASE4":1706,"NA":1708},{"trials":1686,"activeCount":92},[],{"trials":1688,"activeCount":92},[],{"trials":1690,"activeCount":92},[1691],{"nctId":1692,"briefTitle":1693,"status":118,"phases":1694,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":1698,"conditions":1699,"interventions":1700},"NCT01126970","Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects",[83],"2011-01","2011-02","2010-04",486,[15],[1683,1701,1702,1703],"Orlistat 120 mg","Orlistat Placebo","Velneperit Placebo",{"trials":1705,"activeCount":92},[],{"trials":1707,"activeCount":92},[],{"trials":1709,"activeCount":92},[],{"intervention":1701,"totalTrials":136,"cells":1711},{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1716,"PHASE3":1722,"PHASE4":1724,"NA":1726},{"trials":1713,"activeCount":92},[],{"trials":1715,"activeCount":92},[],{"trials":1717,"activeCount":92},[1718],{"nctId":1692,"briefTitle":1693,"status":118,"phases":1719,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":1698,"conditions":1720,"interventions":1721},[83],[15],[1683,1701,1702,1703],{"trials":1723,"activeCount":92},[],{"trials":1725,"activeCount":92},[],{"trials":1727,"activeCount":92},[],{"intervention":1702,"totalTrials":136,"cells":1729},{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1734,"PHASE3":1740,"PHASE4":1742,"NA":1744},{"trials":1731,"activeCount":92},[],{"trials":1733,"activeCount":92},[],{"trials":1735,"activeCount":92},[1736],{"nctId":1692,"briefTitle":1693,"status":118,"phases":1737,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":1698,"conditions":1738,"interventions":1739},[83],[15],[1683,1701,1702,1703],{"trials":1741,"activeCount":92},[],{"trials":1743,"activeCount":92},[],{"trials":1745,"activeCount":92},[],{"intervention":1703,"totalTrials":136,"cells":1747},{"EARLY_PHASE1":1748,"PHASE1":1750,"PHASE2":1752,"PHASE3":1758,"PHASE4":1760,"NA":1762},{"trials":1749,"activeCount":92},[],{"trials":1751,"activeCount":92},[],{"trials":1753,"activeCount":92},[1754],{"nctId":1692,"briefTitle":1693,"status":118,"phases":1755,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":1698,"conditions":1756,"interventions":1757},[83],[15],[1683,1701,1702,1703],{"trials":1759,"activeCount":92},[],{"trials":1761,"activeCount":92},[],{"trials":1763,"activeCount":92},[],{"intervention":1081,"totalTrials":24,"cells":1765},{"EARLY_PHASE1":1766,"PHASE1":1768,"PHASE2":1806,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1767,"activeCount":92},[],{"trials":1769,"activeCount":92},[1770,1774,1786,1798],{"nctId":1072,"briefTitle":1073,"status":118,"phases":1771,"primaryCompletion":1075,"completion":1076,"start":1077,"enrollment":1078,"conditions":1772,"interventions":1773},[82],[15],[1065,1081],{"nctId":1775,"briefTitle":1776,"status":118,"phases":1777,"primaryCompletion":1778,"completion":1779,"start":1780,"enrollment":444,"conditions":1781,"interventions":1783},"NCT04147715","Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults",[82],"2020-09-22","2020-09-29","2019-10-09",[1782],"Healthy Volunteer",[1784,1081,1785],"S-648414","Dolutegravir",{"nctId":1787,"briefTitle":1788,"status":118,"phases":1789,"primaryCompletion":1790,"completion":1791,"start":1792,"enrollment":1793,"conditions":1794,"interventions":1795},"NCT06724978","A Study of S-740792 in Healthy Adult Study Participants",[82],"2025-09-10","2025-09-24","2024-11-21",99,[31],[1796,1081,1797],"S-740792 Suspension","S-740792",{"nctId":1799,"briefTitle":1800,"status":118,"phases":1801,"primaryCompletion":1802,"completion":1802,"start":1803,"enrollment":203,"conditions":1804,"interventions":1805},"NCT05395104","A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants",[82],"2022-07-13","2022-05-24",[33],[1081,783],{"trials":1807,"activeCount":92},[],{"trials":1809,"activeCount":92},[],{"trials":1811,"activeCount":92},[],{"trials":1813,"activeCount":92},[],{"intervention":186,"totalTrials":136,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1824,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1817,"activeCount":92},[],{"trials":1819,"activeCount":92},[1820],{"nctId":177,"briefTitle":178,"status":118,"phases":1821,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":1822,"interventions":1823},[82],[31],[186,79],{"trials":1825,"activeCount":92},[],{"trials":1827,"activeCount":92},[],{"trials":1829,"activeCount":92},[],{"trials":1831,"activeCount":92},[],{"intervention":1833,"totalTrials":136,"cells":1834},"S309309",{"EARLY_PHASE1":1835,"PHASE1":1837,"PHASE2":1849,"PHASE3":1851,"PHASE4":1853,"NA":1855},{"trials":1836,"activeCount":92},[],{"trials":1838,"activeCount":92},[1839],{"nctId":1840,"briefTitle":1841,"status":118,"phases":1842,"primaryCompletion":1843,"completion":1844,"start":1845,"enrollment":203,"conditions":1846,"interventions":1847},"NCT06106334","Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants",[82],"2023-12-08","2024-02-14","2023-11-15",[15,33],[1833,1848],"Itraconazole",{"trials":1850,"activeCount":92},[],{"trials":1852,"activeCount":92},[],{"trials":1854,"activeCount":92},[],{"trials":1856,"activeCount":92},[],{"intervention":1848,"totalTrials":136,"cells":1858},{"EARLY_PHASE1":1859,"PHASE1":1861,"PHASE2":1867,"PHASE3":1869,"PHASE4":1871,"NA":1873},{"trials":1860,"activeCount":92},[],{"trials":1862,"activeCount":92},[1863],{"nctId":1840,"briefTitle":1841,"status":118,"phases":1864,"primaryCompletion":1843,"completion":1844,"start":1845,"enrollment":203,"conditions":1865,"interventions":1866},[82],[15,33],[1833,1848],{"trials":1868,"activeCount":92},[],{"trials":1870,"activeCount":92},[],{"trials":1872,"activeCount":92},[],{"trials":1874,"activeCount":92},[],{"intervention":1876,"totalTrials":136,"cells":1877},"S-888711",{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1891,"PHASE3":1893,"PHASE4":1895,"NA":1897},{"trials":1879,"activeCount":92},[],{"trials":1881,"activeCount":92},[1882],{"nctId":1883,"briefTitle":1884,"status":118,"phases":1885,"primaryCompletion":1886,"completion":1886,"start":1887,"enrollment":1888,"conditions":1889,"interventions":1890},"NCT03897413","Effect of Food and Calcium on Pharmacokinetics of a Single Dose of S-888711 in Healthy Adult Volunteers",[82],"2009-12-23","2009-11-06",15,[1782],[1876],{"trials":1892,"activeCount":92},[],{"trials":1894,"activeCount":92},[],{"trials":1896,"activeCount":92},[],{"trials":1898,"activeCount":92},[],{"intervention":1900,"totalTrials":136,"cells":1901},"S-488210",{"EARLY_PHASE1":1902,"PHASE1":1904,"PHASE2":1920,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1903,"activeCount":92},[],{"trials":1905,"activeCount":92},[1906],{"nctId":1907,"briefTitle":1908,"status":118,"phases":1909,"primaryCompletion":1910,"completion":1910,"start":1911,"enrollment":1912,"conditions":1913,"interventions":1918},"NCT04316689","First-in-human Study of S-588210 (S-488210+S-488211)",[82],"2021-09-22","2019-07-30",10,[1163,1914,1915,1916,1917],"Head and Neck Cancer","Bladder Cancer","Esophageal Cancer","Mesothelioma",[1900,1919],"S-488211",{"trials":1921,"activeCount":92},[],{"trials":1923,"activeCount":92},[],{"trials":1925,"activeCount":92},[],{"trials":1927,"activeCount":92},[],{"intervention":1919,"totalTrials":136,"cells":1929},{"EARLY_PHASE1":1930,"PHASE1":1932,"PHASE2":1938,"PHASE3":1940,"PHASE4":1942,"NA":1944},{"trials":1931,"activeCount":92},[],{"trials":1933,"activeCount":92},[1934],{"nctId":1907,"briefTitle":1908,"status":118,"phases":1935,"primaryCompletion":1910,"completion":1910,"start":1911,"enrollment":1912,"conditions":1936,"interventions":1937},[82],[1163,1914,1915,1916,1917],[1900,1919],{"trials":1939,"activeCount":92},[],{"trials":1941,"activeCount":92},[],{"trials":1943,"activeCount":92},[],{"trials":1945,"activeCount":92},[],{"intervention":1190,"totalTrials":136,"cells":1947},{"EARLY_PHASE1":1948,"PHASE1":1950,"PHASE2":1956,"PHASE3":1958,"PHASE4":1960,"NA":1962},{"trials":1949,"activeCount":92},[],{"trials":1951,"activeCount":92},[1952],{"nctId":1181,"briefTitle":1182,"status":118,"phases":1953,"primaryCompletion":1184,"completion":1184,"start":1185,"enrollment":1186,"conditions":1954,"interventions":1955},[82],[1188],[1174,1190],{"trials":1957,"activeCount":92},[],{"trials":1959,"activeCount":92},[],{"trials":1961,"activeCount":92},[],{"trials":1963,"activeCount":92},[],{"intervention":1784,"totalTrials":136,"cells":1965},{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1967,"activeCount":92},[],{"trials":1969,"activeCount":92},[1970],{"nctId":1775,"briefTitle":1776,"status":118,"phases":1971,"primaryCompletion":1778,"completion":1779,"start":1780,"enrollment":444,"conditions":1972,"interventions":1973},[82],[1782],[1784,1081,1785],{"trials":1975,"activeCount":92},[],{"trials":1977,"activeCount":92},[],{"trials":1979,"activeCount":92},[],{"trials":1981,"activeCount":92},[],{"intervention":1785,"totalTrials":136,"cells":1983},{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":1992,"PHASE3":1994,"PHASE4":1996,"NA":1998},{"trials":1985,"activeCount":92},[],{"trials":1987,"activeCount":92},[1988],{"nctId":1775,"briefTitle":1776,"status":118,"phases":1989,"primaryCompletion":1778,"completion":1779,"start":1780,"enrollment":444,"conditions":1990,"interventions":1991},[82],[1782],[1784,1081,1785],{"trials":1993,"activeCount":92},[],{"trials":1995,"activeCount":92},[],{"trials":1997,"activeCount":92},[],{"trials":1999,"activeCount":92},[],{"intervention":2001,"totalTrials":136,"cells":2002},"Radio-labelled S-770108",{"EARLY_PHASE1":2003,"PHASE1":2005,"PHASE2":2016,"PHASE3":2018,"PHASE4":2020,"NA":2022},{"trials":2004,"activeCount":92},[],{"trials":2006,"activeCount":92},[2007],{"nctId":2008,"briefTitle":2009,"status":118,"phases":2010,"primaryCompletion":2011,"completion":2012,"start":2013,"enrollment":183,"conditions":2014,"interventions":2015},"NCT04631354","Study in Healthy Adults to Quantify Lung Deposition and Distribution of Radio-labelled S-770108 Inhalation Powder Formulation Delivered by a Novel Inhaler Device",[82],"2020-12-14","2020-12-21","2020-11-09",[1782],[2001],{"trials":2017,"activeCount":92},[],{"trials":2019,"activeCount":92},[],{"trials":2021,"activeCount":92},[],{"trials":2023,"activeCount":92},[],{"intervention":2025,"totalTrials":136,"cells":2026},"Standard of Care Antibiotic",{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2041,"PHASE3":2043,"PHASE4":2045,"NA":2047},{"trials":2028,"activeCount":92},[],{"trials":2030,"activeCount":92},[2031],{"nctId":2032,"briefTitle":2033,"status":108,"phases":2034,"primaryCompletion":2035,"completion":2036,"start":2037,"enrollment":16,"conditions":2038,"interventions":2040},"NCT03862040","Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia",[82],"2019-10-08","2019-10-15","2019-02-20",[2039],"Bacterial Pneumonia",[783,2025],{"trials":2042,"activeCount":92},[],{"trials":2044,"activeCount":92},[],{"trials":2046,"activeCount":92},[],{"trials":2048,"activeCount":92},[],{"intervention":2050,"totalTrials":136,"cells":2051},"Ensitrelvir",{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2065,"PHASE3":2067,"PHASE4":2069,"NA":2071},{"trials":2053,"activeCount":92},[],{"trials":2055,"activeCount":92},[2056],{"nctId":2057,"briefTitle":2058,"status":118,"phases":2059,"primaryCompletion":2060,"completion":2060,"start":2061,"enrollment":101,"conditions":2062,"interventions":2064},"NCT06775730","A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants",[82],"2025-04-03","2024-12-30",[2063],"Healthy Adult Female Participants",[2050],{"trials":2066,"activeCount":92},[],{"trials":2068,"activeCount":92},[],{"trials":2070,"activeCount":92},[],{"trials":2072,"activeCount":92},[],{"intervention":1796,"totalTrials":136,"cells":2074},{"EARLY_PHASE1":2075,"PHASE1":2077,"PHASE2":2083,"PHASE3":2085,"PHASE4":2087,"NA":2089},{"trials":2076,"activeCount":92},[],{"trials":2078,"activeCount":92},[2079],{"nctId":1787,"briefTitle":1788,"status":118,"phases":2080,"primaryCompletion":1790,"completion":1791,"start":1792,"enrollment":1793,"conditions":2081,"interventions":2082},[82],[31],[1796,1081,1797],{"trials":2084,"activeCount":92},[],{"trials":2086,"activeCount":92},[],{"trials":2088,"activeCount":92},[],{"trials":2090,"activeCount":92},[],{"intervention":1797,"totalTrials":136,"cells":2092},{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2101,"PHASE3":2103,"PHASE4":2105,"NA":2107},{"trials":2094,"activeCount":92},[],{"trials":2096,"activeCount":92},[2097],{"nctId":1787,"briefTitle":1788,"status":118,"phases":2098,"primaryCompletion":1790,"completion":1791,"start":1792,"enrollment":1793,"conditions":2099,"interventions":2100},[82],[31],[1796,1081,1797],{"trials":2102,"activeCount":92},[],{"trials":2104,"activeCount":92},[],{"trials":2106,"activeCount":92},[],{"trials":2108,"activeCount":92},[],{"intervention":2110,"totalTrials":136,"cells":2111},"S-707106",{"EARLY_PHASE1":2112,"PHASE1":2114,"PHASE2":2127,"PHASE3":2129,"PHASE4":2131,"NA":2133},{"trials":2113,"activeCount":92},[],{"trials":2115,"activeCount":92},[2116],{"nctId":2117,"briefTitle":2118,"status":118,"phases":2119,"primaryCompletion":2120,"completion":2121,"start":833,"enrollment":2122,"conditions":2123,"interventions":2124},"NCT01154348","Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus",[82],"2010-11","2010-12",34,[1261],[2110,2125,2126],"Metformin, S-707106 plus metformin","Metformin, placebo plus metformin",{"trials":2128,"activeCount":92},[],{"trials":2130,"activeCount":92},[],{"trials":2132,"activeCount":92},[],{"trials":2134,"activeCount":92},[],{"intervention":2125,"totalTrials":136,"cells":2136},{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2145,"PHASE3":2147,"PHASE4":2149,"NA":2151},{"trials":2138,"activeCount":92},[],{"trials":2140,"activeCount":92},[2141],{"nctId":2117,"briefTitle":2118,"status":118,"phases":2142,"primaryCompletion":2120,"completion":2121,"start":833,"enrollment":2122,"conditions":2143,"interventions":2144},[82],[1261],[2110,2125,2126],{"trials":2146,"activeCount":92},[],{"trials":2148,"activeCount":92},[],{"trials":2150,"activeCount":92},[],{"trials":2152,"activeCount":92},[],{"intervention":2126,"totalTrials":136,"cells":2154},{"EARLY_PHASE1":2155,"PHASE1":2157,"PHASE2":2163,"PHASE3":2165,"PHASE4":2167,"NA":2169},{"trials":2156,"activeCount":92},[],{"trials":2158,"activeCount":92},[2159],{"nctId":2117,"briefTitle":2118,"status":118,"phases":2160,"primaryCompletion":2120,"completion":2121,"start":833,"enrollment":2122,"conditions":2161,"interventions":2162},[82],[1261],[2110,2125,2126],{"trials":2164,"activeCount":92},[],{"trials":2166,"activeCount":92},[],{"trials":2168,"activeCount":92},[],{"trials":2170,"activeCount":92},[],{"intervention":783,"totalTrials":1912,"cells":2172},{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2185,"PHASE3":2203,"PHASE4":2213,"NA":2215},{"trials":2174,"activeCount":92},[],{"trials":2176,"activeCount":92},[2177,2181],{"nctId":2032,"briefTitle":2033,"status":108,"phases":2178,"primaryCompletion":2035,"completion":2036,"start":2037,"enrollment":16,"conditions":2179,"interventions":2180},[82],[2039],[783,2025],{"nctId":1799,"briefTitle":1800,"status":118,"phases":2182,"primaryCompletion":1802,"completion":1802,"start":1803,"enrollment":203,"conditions":2183,"interventions":2184},[82],[33],[1081,783],{"trials":2186,"activeCount":92},[2187,2191,2195,2199],{"nctId":1027,"briefTitle":1028,"status":118,"phases":2188,"primaryCompletion":1030,"completion":1030,"start":1031,"enrollment":213,"conditions":2189,"interventions":2190},[83],[1033],[783,1018],{"nctId":1036,"briefTitle":1037,"status":118,"phases":2192,"primaryCompletion":1039,"completion":1039,"start":1040,"enrollment":1041,"conditions":2193,"interventions":2194},[83],[1043,779,1044,26,1045,29,780],[783,1018],{"nctId":1422,"briefTitle":1423,"status":118,"phases":2196,"primaryCompletion":1425,"completion":1426,"start":1427,"enrollment":1428,"conditions":2197,"interventions":2198},[83],[1430],[783,1413],{"nctId":1048,"briefTitle":1049,"status":118,"phases":2200,"primaryCompletion":1051,"completion":1051,"start":1052,"enrollment":1053,"conditions":2201,"interventions":2202},[83],[1043,1055,29,1056],[783,1018],{"trials":2204,"activeCount":92},[2205,2209],{"nctId":770,"briefTitle":771,"status":118,"phases":2206,"primaryCompletion":773,"completion":774,"start":775,"enrollment":776,"conditions":2207,"interventions":2208},[84],[778,779,26,29,780,781],[783,759],{"nctId":872,"briefTitle":873,"status":118,"phases":2210,"primaryCompletion":875,"completion":773,"start":876,"enrollment":877,"conditions":2211,"interventions":2212},[84],[778,26,781],[783,861,880],{"trials":2214,"activeCount":92},[],{"trials":2216,"activeCount":92},[2217,2227],{"nctId":2218,"briefTitle":2219,"status":118,"phases":2220,"primaryCompletion":2221,"completion":2221,"start":2222,"enrollment":2223,"conditions":2224,"interventions":2226},"NCT05789199","Use of Cefiderocol in the Management of Gram-Negative Infections",[],"2023-06-16","2022-07-31",314,[2225],"Gram-Negative Infection",[783],{"nctId":2228,"briefTitle":2229,"status":2230,"phases":2231,"conditions":2232,"interventions":2234},"NCT03780140","Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections","APPROVED_FOR_MARKETING",[],[2233],"Bacterial Infections",[783]]